Gene expression profile in a glioma cell line resistant to cell death induced by a the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53-the role of NFκB

Carcinogenesis

Volumn 31, Issue 3, 2010, Pages 411-418

  Seznec, Janina ^a   Weit, Simone ^a   Naumann, Ulrike ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BEX PROTEIN; BINDING PROTEIN; CASPASE; CHIMERIC TUMOR SUPPRESSOR 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BEX1 PROTEIN, HUMAN; CHIMERIC TUMOR SUPPRESSOR 1 PROTEIN; CHIMERIC TUMOR SUPPRESSOR-1 PROTEIN; HYBRID PROTEIN; NERVE PROTEIN; TUMOR PROTEIN;

ARTICLE; CARCINOGENESIS; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; ADENOVIRUS; APOPTOSIS; BIOSYNTHESIS; DOMINANT GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE VECTOR; GENETICS; GLIOMA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; APOPTOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, DOMINANT; GENES, P53; GENETIC VECTORS; GLIOMA; HUMANS; MICROARRAY ANALYSIS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; NF-KAPPA B; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950896821     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp319     Document Type: Article

References (42)

1. Glioma Meta-Analyst Trial Group. (2002) Chemotherapy in adult highgrade glioma: a systematic review and a meta-analysis of individual patient data from 12 randomised trials. Lancet, 359, 1011-1018.
2. Weller, M. et al. (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer, 79, 640-644.
3. Huang, H. et al. (2000) Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res., 60, 6868-6874.
4. Reifenberger, J. et al. (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol., 55, 822-831.
5. Conseiller, E. et al. (1998) CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J. Clin. Invest., 101, 120-127.
6. Naumann, U. et al. (2001) Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res., 61, 5833-5842.
7. Naumann, U. et al. (2006) PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells. Cancer Gene Ther., 13, 469-478.
8. Styczynski, J. et al. (2006) Activity of bortezomib in glioblastoma. Anticancer Res., 26, 4499-4503.
9. Labussiere, M. et al. (2008) Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol. Rep., 20, 1283-1287.
10. Kubicek, G.J. et al. (2009) Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys., 74, 433-439.
11. Sarkar, F.H. et al. (2008) NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol., 27, 293-319.
12. Wischhusen, J. et al. (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene, 22, 8233-8245.
13. Amatya, V.J. et al. (2005) TP53 promoter methylation in human gliomas. Acta Neuropathol. (Berl), 110, 178-184.
14. Weinmann, L. et al. (2008) A novel p53 rescue compound induces p53dependent growth arrest and sensitises glioma cells to Apo2L/TRAILinduced apoptosis. Cell Death Differ., 15, 718-729.
15. Ishii, N. et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9, 469-479.
16. Bhakar, A.L. et al. (2002) Constitutive nuclear factor-kappa B activity is required for central neuron survival. J. Neurosci., 22, 8466-8475.
17. Naumann, U. et al. (2004) Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. Cell Death Differ., 11, 1326-1341.
18. Bonin, M. et al. (2008) Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity. J. Neural. Transm., 115, 941-958.
19. Hermisson, M. et al. (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem., 96, 766-776.
20. Grentzmann, G. et al. (1998) A dual-luciferase reporter system for studying recoding signals. RNA, 4, 479-486.
21. Wick, W. et al. (2006) Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des., 12, 341-349.
22. Koul, D. (2008) PTEN signaling pathways in glioblastoma. Cancer Biol. Ther., 7, 1321-1325.
23. Alvarez, E. et al. (2005) Characterization of the Bex gene family in humans, mice, and rats. Gene, 357, 18-28.
24. Naderi, A. et al. (2007) BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res., 67, 6725-6736.
25. Kostenko, S. et al. (2009) Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci., 66, 3289-3307.
26. Riker, A.I. et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genomics, 1, 13.
27. Lotan, T.L. et al. (2007) Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J. Pathol., 212, 386-394.
28. Bos, P.D. et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature, 459, 1005-1009.
29. Endres, R. et al. (2003) Apparently normal tumor necrosis factor receptor 1 signaling in the absence of the silencer of death domains. Mol. Cell. Biol., 23, 6609-6617.
30. Spanjaard, R.A. et al. (2007) Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int. J. Cancer, 120, 1304-1310.
31. Eckhart, L. et al. (2007) Phylogenomics of caspase-activated DNA fragmentation factor. Biochem. Biophys. Res. Commun., 356, 293-299.
32. Delfino, D.V. et al. (2006) Inhibited cell death, NF-kappaB activity and increased IL-10 in TCR-triggered thymocytes of transgenic mice overexpressing the glucocorticoid-induced protein GILZ. Int. Immunopharmacol., 6, 1126-1134.
33. Fukushima, T. et al. (2007) Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res., 27, 3685-3692.
34. Pen, A. et al. (2008) Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene, 27, 6834-6844.
35. Na, S.Y. et al. (1999) Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. J. Biol. Chem., 274, 28491-28496.
36. Luo, G. et al. (2000) Stat5b inhibits NFkappaB-mediated signaling. Mol. Endocrinol., 14, 114-123.
37. Janssens, S. et al. (2006) Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ., 13, 773-784.
38. Zarnegar, B.J. et al. (2008) Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol., 9, 1371-1378.
39. Vilar, M. et al. (2006) Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J., 25, 1219-1230.
40. Robe, P.A. et al. (2004) In vitro and in vivo activity of the nuclear factorkappaB inhibitor sulfasalazine in human glioblastomas. Clin. Cancer Res., 10, 5595-5603.
41. Angileri, F.F. et al. (2008) Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer, 112, 2258-2266.
42. Sudheerkumar, P. et al. (2008) Independent activation of Akt and NFkappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas. Mol. Carcinog., 47, 126-136.